When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Immunotherapy improves survival in people with advanced ... - AOL

   www.aol.com/news/immunotherapy-improves-survival...

   An immunotherapy approach to treating advanced Hodgkin lymphoma may drastically increase patients’ chances of survival, including those as young as 12, according to a new clinical trial.

3. MOPP (chemotherapy) - Wikipedia

   en.wikipedia.org/wiki/MOPP_(chemotherapy)

   MOPP is a combination chemotherapy regimen used to treat Hodgkin lymphoma. The acronym is derived from the component drugs of the regimen: ustargen (also known as mechlorethamine, chlormethine, mustine, nitrogen mustard, or MSD) ncovin (also known as Vincristine or VCR) rocarbazine (also known as Matulane or Natulan)

4. GVD (chemotherapy) - Wikipedia

   en.wikipedia.org/wiki/GVD_(chemotherapy)

   GVD is a chemotherapy regimen, used for salvage treatment of relapsed or refractory Hodgkin disease, including those patients who relapse after stem cell transplantation. [1] The GVD regimen consists of three drugs, from which its name is derived: Gemcitabine; Vinorelbine; and; Doxil, a pegylated liposomal formulation of doxorubicin.

5. ABVD - Wikipedia

   en.wikipedia.org/wiki/ABVD

   As of 2007, ABVD is widely used as the initial chemotherapy treatment for newly diagnosed Hodgkin lymphoma. [citation needed] It has been the most effective and least toxic chemotherapy regimen available for treating early-stage Hodgkin Lymphoma. [1]

6. COPP (chemotherapy) - Wikipedia

   en.wikipedia.org/wiki/COPP_(chemotherapy)

   COPP is a chemotherapy regimen for treatment of Hodgkin disease, consisting of concurrent treatment with Cyclophosphamide, Oncovin, Procarbazine and Prednisone.. It contains less procarbazine than MOPP (procarbazine is given only for 10 days in cycle instead of 14), and the very toxic mechlorethamine, which is prone to giving severe neutropenia and to severely heighten the risk of secondary ...

7. BEACOPP - Wikipedia

   en.wikipedia.org/wiki/BEACOPP

   BEACOPP is a chemotherapy regimen for treatment of Hodgkin lymphoma developed by the German Hodgkin Study Group [1] used for patients in Stages > II or early (IA or IB) with unfavorable risk factors. [2] Patients typically receive treatment in cycles of 21 days with no drugs given on days 15–21. [3]